

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Zaihui Zhang et al.
Application No. : 10/521,948
Filed : January 23, 2006
For : PYRAZOLYLBENZOTHAZOLE DERIVATIVES AND THEIR
USE AS THERAPEUTIC AGENTS
Examiner : Laura Lynne Stockton
Art Unit : 1626
Docket No. : 540057.418USPC
Date : February 25, 2009

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

2ND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT TRANSMITTAL

Commissioner for Patents:

In accordance with 37 CFR 1.56 and 1.97 through 1.98, Applicants wish to make known to the U.S. Patent and Trademark Office the references set forth on the attached 2nd Supplemental Information Disclosure Statement. Copies of cited U.S. patents and published patent applications are not required and accordingly have not been provided. Copies of any other cited references are enclosed. As to any reference cited, Applicants do not admit that it is “prior art” under 35 U.S.C. §§ 102 or 103, and specifically reserve the right to traverse or antedate any such reference, as by a showing under 37 CFR 1.131 or other method. Although the aforesaid references are made known to the Patent and Trademark Office in compliance with Applicants’ duty to disclose all information they are aware of which is believed relevant to the examination of the above-identified application, Applicants believe that their invention is patentable.

Please acknowledge receipt of this 2nd Supplemental Information Disclosure Statement and kindly make the cited references of record in the above-identified application.

U.S. Application No. 10/521,948
2nd Supplemental Information Disclosure Statement

A fee of \$180 is submitted in accordance with 37 CFR 1.97(c). The Director is authorized to charge any other fees which may be required, or credit any overpayment to Deposit Account No. 19-1090.

Respectfully submitted,

SEED Intellectual Property Law Group PLLC

/Hai Han/

Hai Han, Ph.D.

Registration No. 54,150

HXH:ms

Enclosures:

2nd Supplemental Information Disclosure Statement
Cited References (3)

701 Fifth Avenue, Suite 5400
Seattle, Washington 98104
Phone: (206) 622-4900
Fax: (206) 682-6031

1337539_1.DOC